The involvement of OCTN1 in cancer metabolism, is probably unrelated to the poor ability of this transporter to mediate carnitine transport, however, it is interesting to know that OCTN1 is involved in the uptake of anti-cancer drugs (Table 1) such as Cytarabine (Drenberg et al., 2017), Camptothecin (Zheng et al., 2016), mitoxantrone and doxorubicin (Okabe et al., 2008)
But real-world experience with similar medications (semaglutide, tirzepatide) shows many patients maintain their weight loss on substantially lower doses
Emerging research shows improvement in liver enzymes and reduced liver fat, but they are not yet approved for NAFLD treatment
[DOI] [PMC free article] [PubMed] [Google Scholar] 43.Pan A., Hu F.B
While the specifics may vary, GLP-1 microdosing generally refers to a non-standard dosing regimen in which you take smaller doses or wait longer between doses
In this context, it is important to distinguish between 503A compounding pharmacies and 503B outsourcing facilities
